Biocon Limited — Important, 24-12-2024: Updates

Biocon Limited and its European partner, Zentiva, have secured De-centralized Procedure (DCP) approval for the complex formulation Liraglutide in the European Union. This approval pertains to the generic versions of Victoza® (for Type-2 Diabetes treatment) and Saxenda® (for weight management). This strategic development opens up significant market opportunities in the EU, potentially enhancing revenue growth for Biocon while addressing critical healthcare needs. Stakeholders should monitor this progress closely, as successful commercialization could positively influence the company's market position and financial performance in this segment.